Drugs / SPRIX (intranasal ketorolac tromethemine)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01819610 | Feb 2013 → Mar 2014 | — | American Regent, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPRIX (intranasal ketorolac tromethemine) | “SPRIX (intranasal ketorolac tromethemine)” NCT01819610 ↗ |
| Known as | SPRIX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01819610 ↗ |
| Route | Intranasal | “This is a study of intranasal (IN) ketorolac tromethamine (SPRIX)” NCT01819610 ↗ |